Action 13
Committed by:
In pre-clinical and clinical development, initiate paediatric formulation development as soon as a given drug shows potential public health impact in adults, soon after Phase II trials are completed.
Pharmaceutical companies
Sub-Actions & Milestones
Sub-action 13.1
Initiate paediatric formulation development as soon as a given drug shows potential public health impact in adults, soon after Phase II trials are completed.
Pharmaceutical companies
ViiV will be increasing resources in Pediatrics further by appointing a Medicine Development Lead to span across the whole R&D portfolio to address these actions.
-
Milestone 13.1.1
Review ARV portfolio, prioritize PADO products and communicate changes with stakeholders
Pharmaceutical companies
-
-
Milestone. 13.1.2
Demonstrate timely implementation of PADO priorities as part of paediatric portfolio
Pharmaceutical companies
-
-
Updates
Notes
Responsible